132 related articles for article (PubMed ID: 16414330)
21. Can we predict who will experience recurrent vasomotor symptoms after stopping hormone therapy?
Gracia CR; Sondheimer S
Menopause; 2010; 17(1):10-1. PubMed ID: 20010441
[No Abstract] [Full Text] [Related]
22. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.
Osborne CR; Duncan A; Sedlacek S; Paul D; Holmes F; Vukelja S; Kasper M; Wilks S; Schneider A; McGee R; Meyer WG; O'Shaughnessy JA
Breast Cancer Res Treat; 2009 Aug; 116(3):521-7. PubMed ID: 19139988
[TBL] [Abstract][Full Text] [Related]
23. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
[TBL] [Abstract][Full Text] [Related]
24. US women desire greater professional guidance on hormone and alternative therapies for menopause symptom management.
Ma J; Drieling R; Stafford RS
Menopause; 2006; 13(3):506-16. PubMed ID: 16735949
[TBL] [Abstract][Full Text] [Related]
25. ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease.
American College of Obstetricians and Gynecologists Committee on Gynecologic Practice
Obstet Gynecol; 2008 Nov; 112(5):1189-92. PubMed ID: 18978127
[TBL] [Abstract][Full Text] [Related]
26. Treatment of menopausal vasomotor symptoms.
Med Lett Drugs Ther; 2004 Dec 6-20; 47(1197-1198):98-9. PubMed ID: 15583526
[TBL] [Abstract][Full Text] [Related]
27. NAMS 3rd Utian Translational Science Symposium, October 2016, Orlando, Florida A conversation about hormone therapy: is there an appropriate dose, route, and duration of use?
The North American Menopause Society (NAMS)
Menopause; 2017 Nov; 24(11):1221-1235. PubMed ID: 28968302
[TBL] [Abstract][Full Text] [Related]
28. Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen.
Simon JA; Snabes MC
Expert Opin Investig Drugs; 2007 Dec; 16(12):2005-20. PubMed ID: 18042008
[TBL] [Abstract][Full Text] [Related]
29. Hot flashes and estrogen therapy do not influence cognition in early menopausal women.
LeBlanc ES; Neiss MB; Carello PE; Samuels MH; Janowsky JS
Menopause; 2007; 14(2):191-202. PubMed ID: 17194963
[TBL] [Abstract][Full Text] [Related]
30. Low and ultra low-dose estrogen therapy for climacteric symptom control--preliminary report.
Carranza-Lira S; Gooch AL; Velasco-Díaz G; Solano J; Arzola-Paniagua A
Int J Fertil Womens Med; 2006; 51(4):171-5. PubMed ID: 17184102
[TBL] [Abstract][Full Text] [Related]
31. Benefits and risks of long-term low-dose oral continuous combined hormone therapy.
van de Weijer PH; Mattsson LA; Ylikorkala O
Maturitas; 2007 Mar; 56(3):231-48. PubMed ID: 17034966
[TBL] [Abstract][Full Text] [Related]
32. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
[TBL] [Abstract][Full Text] [Related]
33. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation.
Grodstein F; Manson JE; Stampfer MJ
J Womens Health (Larchmt); 2006; 15(1):35-44. PubMed ID: 16417416
[TBL] [Abstract][Full Text] [Related]
34. Discontinuing postmenopausal hormone therapy: an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms?
Haskell SG; Bean-Mayberry B; Gordon K
Menopause; 2009; 16(3):494-9. PubMed ID: 19182695
[TBL] [Abstract][Full Text] [Related]
35. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
36. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L
Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736
[TBL] [Abstract][Full Text] [Related]
37. Drug delivery systems for hormone therapy.
Yoo JW; Lee CH
J Control Release; 2006 May; 112(1):1-14. PubMed ID: 16530874
[TBL] [Abstract][Full Text] [Related]
38. MF-101, an estrogen receptor beta agonist for the treatment of vasomotor symptoms in peri- and postmenopausal women.
Stovall DW; Pinkerton JV
Curr Opin Investig Drugs; 2009 Apr; 10(4):365-71. PubMed ID: 19337958
[TBL] [Abstract][Full Text] [Related]
39. Ultra-low dose - new approaches in menopausal hormone therapy.
Stute P; Becker HG; Bitzer J; Chatsiproios D; Luzuy F; von Wolff M; Wunder D; Birkhäuser M
Climacteric; 2015 Apr; 18(2):182-6. PubMed ID: 25335192
[TBL] [Abstract][Full Text] [Related]
40. Attitudes of Korean clinicians to postmenopausal hormone therapy after the Women's Health Initiative study.
Kang BM; Kim MR; Park HM; Yoon BK; Lee BS; Chung HW; Cho SH; Choi H; Kim JG
Menopause; 2006; 13(1):125-9. PubMed ID: 16607108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
